1,101 results on '"Toto, Robert"'
Search Results
202. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis
203. ACE inhibitors and target organ protection: An expanded role for these antihypertensive agents?
204. Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis
205. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study
206. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)
207. Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease: A Meta-Analysis of Patient-Level Data
208. Angiotensin II Subtype 1 Receptor Blockers and Renal Function
209. Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis: A Randomized Controlled Trial
210. Longitudinal and cross-sectional effects of C-reactive protein, equilibrated normalized protein catabolic rate, and serum bicarbonate on creatinine and albumin levels in dialysis patients
211. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK)
212. Sympathetic overactivity in patients with chronic renal failure
213. Allergic Interstitial Nephritis Due to Diuretic Agents
214. Metabolic Derangements Associated with Diuretic Use
215. Outcome studies in diabetic nephropathy
216. Effect of Intensive Blood Pressure Control on Aortic Stiffness in the SPRINT-HEART.
217. Hypertension in patients with diabetes: overcoming barriers to effective control
218. MOESM1 of Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINAÂŽ): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
219. Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials
220. Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
221. Effect of Blood Pressure Control on Long‐Term Risk of End‐Stage Renal Disease and Death Among Subgroups of Patients With Chronic Kidney Disease
222. Kidney Tubular Damage and Functional Biomarkers in Acute Kidney Injury Following Cardiac Surgery
223. Low Serum Magnesium is associated with Faster Decline in Kidney Function: The Dallas Heart Study Experience
224. 388-P: Interrelationship between Hypoglycemia and CV and Mortality Outcomes in Type 2 Diabetes in the CARMELINA Trial
225. 432-P: Analyses of First plus Recurrent Cardiovascular and Hospitalization Events in the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) in Patients with Type 2 Diabetes and Cardiorenal Disease
226. Urine Klotho Is Lower in Critically Ill Patients With Versus Without Acute Kidney Injury and Associates With Major Adverse Kidney Events
227. Count me in: using a patient portal to minimize implicit bias in clinical research recruitment
228. Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
229. Abstract #289 Effect of Linagliptin on Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes and Kidney Disease: Carmelina®
230. SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA
231. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
232. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
233. Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
234. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
235. Impact of Acute Kidney Injury and CKD on Adverse Outcomes in Critically Ill Septic Patients
236. Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Outcomes After Intensive Blood Pressure Lowering: Findings From the SPRINT Randomized Clinical Trial
237. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure
238. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
239. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
240. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy
241. Assessing the evolution of atherosclerotic renal artery stenosis
242. Importance of trial design when investigating cardiorenal outcomes in patients with CKD and T2D: Focus on CREDENCE and FIDELIO-DKD
243. Accrual to Clinical Trials (ACT): A Clinical and Translational Science Award Consortium Network.
244. Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial.
245. The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy
246. Reversible Renal Insufficiency due to Angiotensin Converting Enzyme Inhibitors in Hypertensive Nephrosclerosis
247. Acute Tubulointerstitial Nephritis
248. HYPOKALEMIC NEPHROPATHY — A CLUE TO CYSTOGENESIS?
249. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
250. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.